Search clinical trials for: fluticasone/salmeterol 250/50 Dry Powder Inhaler

Total 236 results

Nemours Children's Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial (MICT)

Asthma

United States
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers (PIFECO)

Pulmonary Disease, Chronic Obstructive | Asthma

United Kingdom, Finland
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Esfam Biotech Pty Ltd

Not yet recruiting

A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects

COVID-19
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Vectura Limited
UCB Pharma

Completed

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

Asthma

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
GB002, Inc.

Not yet recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Pulmonary Arterial Hypertension

United States
GB002, Inc.

Recruiting

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Pulmonary Arterial Hypertension

United States, Spain, Israel, Korea, Republic of, Netherlands, France, Singapore, United Kingdom, Lithuania, Australia, Latvia, Argentina, Portugal, Greece, Czechia, Puerto Rico, Belgium, Italy, Poland, Romania, Serbia, Austria, Chile, Denma... and more
GB002, Inc., a wholly owned subsidiary of Gossamer...

Recruiting

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, United Kingdom
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
GlaxoSmithKline

Completed

A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control

Asthma

Denmark, Switzerland
GB002, Inc., a wholly owned subsidiary of Gossamer...
Worldwide Clinical Trials; Pulmokine Inc.

Completed

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Safety Issues

United States
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Artery Hypertension

United States, Spain, Australia, Germany, Serbia, Czechia, Belgium, Canada, Austria, France, United Kingdom
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Bioequivalence

Greece
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Organon and Co

Completed

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
GlaxoSmithKline

Completed

Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

Asthma

Germany
Receptor Life Sciences

Withdrawn

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

Social Anxiety Disorder

United States
Neutec Ar-Ge San ve Tic A.Ş

Terminated

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (COPD)

COPD

Turkey
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

Asthma
Medisol Development Kft.
University of Debrecen; St. Borbala Hospital; Pest County Pulmonology Hospital; Medical Centre Hungarian Defence Forces and other collaborators

Active, not recruiting

Breathing Parameter Measurements for Lung Deposition Simulation (CHOICE)

Asthma | COPD

Hungary
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
AstraZeneca

Completed

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma

Germany
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
Milton S. Hershey Medical Center
GlaxoSmithKline

Completed

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

COPD

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
Gary L. Pierce

Completed

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

COPD

United States
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

Chronic Obstructive Pulmonary Disease | COPD
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
GlaxoSmithKline

Completed

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Romania, Russian Federation, United States, Ukraine
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Asthma

Germany, Netherlands, United Kingdom, China, Romania, Bulgaria
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Norway

3

Subscribe